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It has been demonstrated that potassium channels (K+ channels) play signiﬁcant roles in some
malignant phenotypes. Here, we provide the ﬁrst evidence that treatment with glybenclamide, an
ATP-sensitive K+ channel blocker, inhibited cell migration in an ovarian clear cell carcinoma cell
line, ES-2. Treatment with glybenclamide or knockdown by siRNA targeted against K+ channel sub-
units demonstrated the suppression of ovarian cancer cell invasion, which occurred via inhibition of
PDGF-AA secretion. Therefore, our ﬁndings suggest that K+ channel blockers may be useful chemo-
therapeutic drugs for blocking the invasiveness of ovarian cancers.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ovarian cancer is the major cause of deaths from gynecologic
malignancies and the 5th leading cause of cancer-related deaths
among women in the world. About 225,500 new cases had been
expected worldwide in 2008, and 140,200 patients were estimated
to succumb to the disease. Especially the incidence rates are the
highest in developed countries [1]. Although women with organ-
conﬁned tumors have a good prognosis, many ovarian cancer
patients present with advanced stage (FIGO stages III and IV) of
the disease; and the 5-year survival rate for them is about 30%.
On the basis of morphological criteria, ovarian adenocarcinomas
are classiﬁed into four major histological subtypes: serous,
mucinous, endometrioid, and clear cell [2,3]. Clear cell carcinomas
constitute fewer than 10% of all epithelial ovarian cancers; how-
ever, a number of studies have reported that clear cell carcinomas
have a particularly poor prognosis, because of their resistance to
conventional platinum- or taxane-based chemotherapy [4].
Furthermore, clear cell carcinomas exhibit more frequent early
metastasis to lymph nodes and parenchymal organs, resulting in
a high degree of recurrence [5–7].
Potassium channels (K+ channels), one of key players for con-
trolling the membrane potential, are diverse and ubiquitous ion
channels involved in various cellular functions such as prolifera-chemical Societies. Published by E
ezawa).tion, solute transport, volume control, enzyme activities, secretion,
and intercellular communication [8]. It has been demonstrated
that K+ channels have signiﬁcant roles in some malignant cancers
by regulating proliferation, metastasis, and apoptosis [9–11].
Among many K+ channels, ATP-sensitive K+ channels (KATP chan-
nels) are inhibited when the ATP concentration at the cytoplasmic
surface is increased [12]. KATP channels are octameric complexes
comprising four Kir6.0 subunits (containing Kir6.1 or Kir6.2) [13],
members of the inwardly rectifying K+ channel family, and four
sulfonylurea receptor (SUR) subunits (including SUR1, SUR2A, or
SUR2B) [14–16]. The Kir6.0 subunit forms the pore of the KATP
channel complex, whereas the SUR subunit acts as a regulator of
KATP channel activity with sensitivity to sulphonylureas [17–19].
KATP channels are expressed in many tissues including cancer
[9,18]. KATP channels in pancreatic b-cells are associated with insu-
lin secretion [20]. This is the reason why treatment with sulpho-
nylureas, which close KATP channels, stimulates insulin secretion
and why KATP channel openers conversely inhibit insulin release
by activating KATP channels [21,22]. KATP channel blockers includ-
ing glybenclamide are widely used for the treatment of type II dia-
betes mellitus.
In the present study, we found that both paxilline, a BK channel
blocker, and glybenclamide, a KATP channel blocker, inhibited cell
invasion and migration of ovarian clear cell carcinoma ES-2 cells.
Moreover, our results demonstrate that inactivation of KATP
channels suppressed ovarian cancer cell invasion via inhibition of
PDGF-AA secretion. Therefore, our ﬁndings suggest that K+ channellsevier B.V. All rights reserved.
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Fig. 1. KþATP channel blocker inhibited cell invasiveness and migration of ES-2 cells. (A) ES-2 cells were incubated with various concentrations of glybenclamide in a chamber
for 24 h. After removing the cells that remained on the upper side, the cells that had migrated to the lower side of the membrane were counted (closed bars). Asterisks denote
a statistically signiﬁcant (P < 0.0001 by ANOVA) difference between treatment with reagents and vehicle treatment. The effect of glybenclamide on the cell number was also
examined (closed squares). (B) An artiﬁcial wound was created by a pipette tip. The ES-2 cells were then treated with various concentrations of glybenclamide. After 24 h,
photographs were taken by phase-contrast microscopy. Asterisks denote a statistically signiﬁcant (P < 0.0001 by ANOVA) difference between glybenclamide treatment and
vehicle treatment. (C) Analysis of KATP channel activation by use of the potassium ion channel assay. Cells were loaded with dye and then treated with 0 lg/ml (closed
diamonds), 10 lg/ml (closed circles), 30 lg/ml (closed squares), or 100 lg/ml (closed triangles) glybenclamide for 30 min. The arrow shows the time at which the KATP
channels were stimulated as described in Section 2.
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Fig. 2. Regulation of ES-2 cell invasion by SUR2B. (A) Total RNAswere extracted from
exponentially growing ES-2 cells and reacted with reverse transcriptase. Expression
levels of KATP channel subunits and b-actin were assessed by semi-quantitative RT-
PCR. (B) ES-2 cells were incubated in a chamber for 24 h after transfection with
siRNAs targeted to luciferase (siLuc; closed bars) and to SUR2B (siSUR2B; open bars).
The cells that hadmigrated to the lower side of themembranewere counted. Asterisk
denotes a statistically signiﬁcant (P < 0.0001 by ANOVA) difference compared with
siLuc treatment. Silencing of SUR2B expression by the treatment with siSUR2B was
conﬁrmed by semi-quantitative RT-PCR (insert).
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siveness of ovarian cancers.
2. Materials and methods
2.1. Materials
Glybenclamide (M.W. is 494; 10 lg/ml equals 20.2 lM) and
diazoxie (M.W. is 230; 10 lg/ml equals 43.5 lM) were purchased
from Sigma–Aldrich and Enzo Life Sciences (Farmingdale, NY),
respectively. Recombinant human PDGF-AA was purchased from
Peprotech (Rocky Hill, NJ).
2.2. Cell culture
Human ovarian clear cell carcinoma ES-2 cells were cultured in
DMEM containing 10% fetal bovine serum (FBS), 100 units/ml pen-
icillin G, 200 mg/l kanamycin, 600 mg/l L-glutamine, and 2.25 g/l
NaHCO3 at 37 C in a humidiﬁed atmosphere with 5% CO2.
2.3. Assays for invasion, wound healing, cell growth, KATP channel
activity, RT-PCR, siRNA treatment, angiogenesis proteome proﬁling,
Western blotting, ELISA for PDGF-AA, and ﬂuorescence microscopy
The protocols used for the invasion, wound healing, KATP chan-
nel activity, RT-PCR, siRNA treatment, angiogenesis proteome pro-
ﬁling, Western blotting, ELISA for PDGF-AA, and ﬂuorescence
microscopy are indicated in Supplementary Materials and Methods
[23–25].
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3.1. KþATP channel blocker inhibited cell invasion and migration of ES-2
cells
We screened low-molecular weight compounds among
microbial metabolites for their anti-invasive effect, as assessedglybenclamid
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Fig. 3. Inhibition of PDGF-AA secretion by the treatment with glybenclamide. (A) ES-2 c
were extracted at each time point, and expression levels of PDGF-A and b-actin were e
glybenclamide for the indicated times. Intracellular proteins were collected, and expre
indicated antibodies. (C) ES-2 cells were incubated without (closed bars) or with 100 lg/
AA were assessed by ELISA as described in Section 2. Asterisks denote a statistically sign
cells were treated or not with 100 lg/ml glybenclamide for 24 h, and then ﬁxed. The sam
were observed under ﬂuorescence microscope. Bar, 10 lm.by performing the wound healing assay. As a result, we succeeded
in isolating paxilline as an inhibitor of cancer cell migration. Paxil-
line is known to be a blocker of high conductance Ca2+-activated K+
channels. We found that paxilline inhibited ovarian clear cell
carcinoma ES-2 cell invasion (data not shown). On the basis of this
result, we focused on glybenclamide, a KATP channel blocker.
Because glybenclamide is an oral drug widely used in treatmente 100 μg/ml
16 24 (h)
2416 (h)
16 24 (h)
e 100 μg/ml
*
*
glybenclamide
ells were treated with 100 lg/ml glybenclamide for the indicated times. Total RNAs
xamined by semi-quantitative RT-PCR. (B) ES-2 cells were treated with 100 lg/ml
ssion levels of PDGF-A and GAPDH were examined by Western blotting using the
ml glybenclamide (open bars) for the indicated times. The secretion levels of PDGF-
iﬁcant (P < 0.001 by ANOVA) difference compared with vehicle treatment. (D) ES-2
ples were stained with anti-PDGF-A antibody (green) and Hoechst33258 (blue), and
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drug. As shown in Fig. 1A, treatment with glybenclamide inhibited
cell invasion at the concentrations unaffecting the cell growth. Fur-
thermore, glybenclamide inhibited cell migration in the wound
healing assay (Fig. 1B). To examine whether the inhibition of inva-
sion and migration by glybenclamide was due to the blockage of
KATP channels, we measured KATP channel activity in ES-2 cells.
Treatment with glybenclamide suppressed the KATP channel
activity in a dose-dependent manner (Fig. 1C). Thus, these results
suggested that glybenclamide suppressed the invasion and migra-
tion of ES-2 cells, which possessed glybenclamide-sensitive KATP
channel activity.
3.2. Knockdown of SUR2B expression suppressed invasion of ES-2 cells
As KATP channels are known to be an octameric complex of
Kir6.0 and SUR subunits, we examined the mRNA expression levels
of Kir6.0s and SURs in ES-2 cells. As shown in Fig. 2A, ES-2 cells
predominantly expressed Kir6.2 and SUR2B. This ﬁnding is consis-
tent with other studies showing that, in general, KATP channels in
smooth muscle are composed of the Kir6.2/SUR2B or Kir6.1/SUR2B
form [26,27]. Next, to investigate the association of SUR2B with the
ES-2 cell invasion, we treated ES-2 cells with siRNAs against SUR2B
or luciferase. Knockdown of SUR2B suppressed the invasive ability
of the ES-2 cells (Fig. 2B), indicating that SUR2B was associated
with ES-2 cell invasion. Moreover, knockdown of SUR2B with an-
other sequence of siRNAs against SUR2B and Kir6.2 suppressed cell
invasion (data not shown), indicating that glybenclamide probably
bound to SUR2B to suppress the ES-2 cell invasion.
3.3. Inhibition of PDGF-AA secretion by the treatment with
glybenclamide
As demonstrated above, inhibition of K+ channel activity re-
sulted in suppression of ES-2 cell invasion and migration. Thus,
we sought to identify the molecule(s) responsible for the suppres-
sion of ES-2 cell invasion by the treatment with glybenclamide. We
carried out a proteomic analysis on proteins in the conditionedPDGFRα 
β-actin
glybenclamide 100 μg/ml
0 8 16 24 (h)
B
A
0 8 16 24 (h)
glybenclamide 100 μg/ml
GAPDH
PDGFRα 
Fig. 4. Effect of glybenclamide on the expression of PDGFRa. (A) ES-2 cells were
treated with 100 lg/ml glybenclamide for the indicated times. Total RNAs were
extracted at each time point, and expression levels of PDGFRa and b-actin were
examined by semi-quantitative RT-PCR. (B) ES-2 cells were treated with 100 lg/ml
glybenclamide for the indicated times. The expression levels of PDGFRa and GAPDH
were detected by Western blotting using anti-PDGFRa and anti-GAPDH antibodies.medium, and evaluated the relative expression levels of 55 angio-
genesis-related proteins. The secretion of several proteins, such as
endostatin, angiogenin, and PDGF-AA, was decreased by the treat-
ment with glybenclamide (Table 1).
A number of different signaling pathways controlling cell
growth, migration, and differentiation are initiated by the activated
PDGF receptor a, to which PDGF-AA binds [28]; and so we focused
on the effect of glybenclamide on the expression of PDGF-AA. RT-
PCR analysis showed that the expression of PDGF-A mRNA was
not changed by the treatment with glybenclamide (Fig. 3A). Fur-
thermore, Western blotting data demonstrated no prominent effect
of glybenclamide on the amount of intracellular PDGF-A (Fig. 3B).
On the basis these results, we hypothesized that treatment with
glybenclamide might have impaired the secretion of PDGF-AA. To
test this hypothesis, we carried out ELISA analysis of the condi-
tioned media and found that glybenclamide markedly inhibited
the secretion of PDGF-AA into themedium (Fig. 3C), suggesting that
an autocrine system of PDGF signaling may be involved in the inva-
siveness of ES-2 cells. Because PDGF-AA was secreted into the cul-
turedmedium via the ER-to-Golgi apparatus, we next examined the
intracellular localization of PDGF-AA after glybenclamide treat-
ment. Untreated cells stained with anti-PDGF-A antibody showed
ﬂuorescence in the peripheral membrane area (Fig. 3D). Use of an
ER-speciﬁc (anti-PDI) antibody and a Golgi apparatus-speciﬁc
(anti-GRASP65) antibody demonstrated that PDGF-AA was not
present in the Golgi apparatus or ER (Fig. 3D and data not shown),
indicating that PDGF-AAmight have tended to be transported faster
to the peripheral area after translation. Subsequently, we examined
the effect of glybenclamide treatment on the localization of PDGF-
AA. As shown in Fig. 3D, PDGF-AA reached the peripheral mem-
brane area just as in the case of the untreated cells, suggesting that
KATP channels regulate the terminal PDGF-AA secretion process but
not the intracellular trafﬁcking.
PDGFRa is a transmembrane receptor tyrosine kinase activated
by PDGF-AA. Therefore, we next examined the effect of glybencla-
mide on the expression of PDGFRa. RT-PCR analysis and Western
blotting showed that the treatment with glybenclamide did not af-
fect the expression of PDGFRa at either the mRNA (Fig. 4A) or pro-
tein (Fig. 4B) levels. Moreover, treatment with PDGF-AA of ES-2
cells activated KATP channel activity (Supplementary Fig. 1). Thus,
our data suggested that an autocrine system of PDGF signaling in
ES-2 cells would be regulated by KATP channels through the secre-
tion of PDGF-AA.
3.4. Involvement of PDGF-AA signaling in ES-2 cell invasion
To conﬁrm whether an autocrine system of PDGF signaling
contributed to invasion by ES-2 cells, we evaluated the effect ofTable 1
List of proteins decreased in expression by the treatment with glybenclamide.
Protein names Expression level (% of control)
Endostatin 19.4
Angiopoietin-2 21.8
Angiogenin 24.3
IGFBP-3 24.8
Activin A 25.8
PDGF-AA 29.7
PIGF 33.2
VEGF-C 35.9
Endothelin-1 38.4
Endoglin 45.3
Human angiogenesis array was used to detect proteins secreted from ES-2 cells into
the culture medium. ES-2 cells were treated as described in Section 2. The
expression levels were calculated by using the following formula: [expression level
(%) = (protein level after treatment with glybenclamide  background value)/(pro-
tein level after treatment with DMSO  background value)  100]. The top 10
proteins whose expression levels were decreased by the treatment are listed.
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cells. As shown in Fig. 5A, PDGF-AA stimulated ES-2 cell invasion
about 40% and clearly enhanced the invasion about 4 times in gly-
benclamide-treated ES-2 cells. Finally, for performing knockdown
experiments onPDGF-AA,weprepared three different sequence siR-
NAs and conﬁrmed the knockdown of PDGF-A expression (Fig. 5B).
siPDGF-A-1 had the highest knockdown efﬁciency among the three
siRNAs; and siPDGF-A-3, the lowest. Treatment of ES-2 cells with
siPDGF-A-1-3 silenced the PDGF-A expression, resulting in sup-
pressed cell invasion in a knockdown efﬁciency-dependent manner
(Fig. 5B and C). Therefore, these results support our contention that
the KATP channels-regulated autocrine system of PDGF signaling
played an important role in the invasiveness property of ES-2 cells.
4. Discussion
PDGF has been directly implicated in many developmental and
physiological processes, as well as in human cancer, ﬁbrotic dis-
eases, and arteriosclerosis. Human PDGF is produced and functions
as a dimer of two polypeptide chains, A and B. Thus, PDGF can form
three isoforms, PDGF-AA, PDGF-AB, and PDGF-BB [29]. Receptors of
PDGF, PDGFRa and PDGFRb are transmembrane receptorsB
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Fig. 5. Involvement of PDGF autocrine system in ES-2 cell invasion. (A) ES-2 cells were p
PDGF-AA in a chamber for 24 h. The cells that had migrated to the lower side of the mem
As (siPDGF-A-1, siPDGF-A-2, or siPDGF-A-3), and then total RNAs were extracted. After r
semi-quantitative RT-PCR. (C) ES-2 cells were treated with the indicated siRNAs and then
membrane were counted. Asterisks denote a statistically signiﬁcant (P < 0.001 by ANOVpossessing tyrosine kinase activity. PDGFRa homodimers bind
PDGF isoforms [30]. After binding of PDGF-AA to PDGFRa, PDGFRa
undergoes dimerization and autophosphorylation, followed by
interaction with and activation of several proteins containing
SH2 domains, such as MAPK, PI3 kinase, Src, SHP-2, Crk, and PLCc,
to stimulate cell proliferation and migration [31].
In the present study, we demonstrated that glybenclamide, a
KATP channel blocker, suppressed ovarian clear cell invasion by
inhibiting PDGF-AA secretion. The dose range of glybenclamide
for inhibiting KATP channel activity was closely related to that for
suppression of ES-2 cell invasion (Fig. 1B and D). Moreover, treat-
ment with diazoxide, a KATP channel opener, enhanced cell inva-
sion of ES-2 cells (Supplementary Fig. 2). These results suggest
that KATP channel positively regulated ovarian clear cell
invasiveness.
Our proteomics approach demonstrated that treatment of the
ES-2 cells with glybenclamide decreased the amount of several
angiogenesis-related proteins in the conditionedmedium (Table 1).
In this study, we took particular note of PDGF-AA, because it has
been reported that the autocrine system of PDGFs promotes the
progression of ovarian cancer [32]. The amount of PDGF-AA in
the conditioned medium was decreased by the treatment with0
100
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80
C
+
+
PDGF-AA
glybenclamide
* *
reincubated with 100 lg/ml glybenclamide for 2 h, and then treated with 25 ng/ml
brane were counted. (B) ES-2 cells were treated with siLuc or three different siPDGF-
everse transcription, the expression levels of PDGF-A and b-actin were analyzed by
incubated in a chamber for 24 h. The cells that had migrated to the lower side of the
A) difference compared with vehicle treatment.
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levels of PDGF-A (Fig. 3) or PDGFRa (Fig. 4) in the cells. Moreover,
the treatment with glybenclamide did not affect the amount of
PDGF-AB in the proteome proﬁling (data not shown), indicating
that glybenclamide inhibited the secretory mechanism of PDGF-
AA to decrease the ability of the cells to invade. Although PDGF-
AA would be expected to have accumulated inside the cell when
secretion of PDGF-AA was suppressed, the amount of intracellular
PDGF-A protein did not increase (Fig. 3B). We hypothesize that
there were many more PDGF-AA molecules that remained in the
cells than were secreted, thus making it difﬁcult to detect the accu-
mulation after the treatment with glybenclamide.
To demonstrate that the autocrine system of PDGF-AA was
associated with invasiveness, we tested whether suppression of
cell invasion could be recovered by stimulation of the cells with
PDGF-AA. Actually, stimulation by PDGF-AA enhanced cell invasion
regardless of treatment with glybenclamide (Fig. 5A); additionally,
the knockdown of PDGF-A suppressed cell invasion (Fig. 4B and C).
Taken together, our present results indicate that glybenclamide
inhibited the autocrine system of PDGF, thus suppressing cell inva-
siveness. On the other hand, the secretion of some other secretory
proteins, such as PDGF-AB, MMP-9, and TIMP-4, did not change or
was actually increased by the treatment with glybenclamide (data
not shown). Therefore, some speciﬁc regulation system(s) for the
secretion of speciﬁc proteins might be present. Further studies
are needed to explore this possibility.
Glybenclamide is an orally active drug widely used in the treat-
ment of type II diabetes. As of 2011, it is one of the two oral anti-
diabetes drugs in the WHO Model List of Essential Medicine [33],
and has fewer side effects than existing anti-metastatic agents.
Components of KATP channels vary according to tissue, and each
KATP channel has different sensitivities to drugs [34]. Our results
imply an important relation between KATP channels and the meta-
static ability of ovarian cancer and suggest that KATP channels
would be an attractive target for ovarian cancer cell invasion.
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